Pfizer Raises Outlook as Bourla Bets on Obesity — SkimNews
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Bourla is betting the Viagra playbook can crack the obesity market, pointing the sales approach behind Pfizer's signature brand at a new therapeutic area.
- Pfizer raised its full-year profit and revenue outlook on new-product growth and solid demand for a blood thinner, extending the broader pharma windfall Bloomberg highlighted.
Why it matters: Two engines now prop up Pfizer's raised outlook: new products already growing and solid demand for a blood thinner, giving shareholders a firmer near-term earnings picture. Bourla's obesity move is the second front, pointing the Viagra playbook at a market this coverage treats as still uncracked.
Ask SkimNews
